Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878030 · ClinicalTrials.gov registry record
Effect of Nusinersen on Adults With Spinal Muscular Atrophy
A clinical trial of Adult Spinal Muscular Atrophy, sponsored by Northwell Health.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT03878030: Completed study of Adult Spinal Muscular Atrophy, sponsored by Northwell Health.
NCT03878030 is a study of Adult Spinal Muscular Atrophy that has completed, run by Northwell Health. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03878030, a study of Adult Spinal Muscular Atrophy, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Observational study of adult patients with spinal muscular atrophy types 2 and 3 receiving nusinersen
Primary Outcome
Primary Endpoint: Change from baseline to end of study in quantitative motor strength by dynamometry of upper limb muscles - shoulder abduction and elbow flexion/extension.
Conditions Studied
Interventions
- DRUG nusinersen
Study Locations (1)
New York
- Northwell Health Neuroscience - Great Neck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-07-13 |
What the finished NCT03878030 record still lists
NCT03878030 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 1 condition, with Adult Spinal Muscular Atrophy appearing as the primary indexed condition, and to 1 intervention - of which nusinersen is the first listed.
NCT03878030 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03878030 about?
NCT03878030 is a clinical study titled "Effect of Nusinersen on Adults With Spinal Muscular Atrophy". Observational study of adult patients with spinal muscular atrophy types 2 and 3 receiving nusinersen
What is the current status of trial NCT03878030?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2019-04-01. Estimated completion is 2021-07-13.
What conditions does trial NCT03878030 study?
This clinical trial studies the following conditions: Adult Spinal Muscular Atrophy.
What interventions are being tested in trial NCT03878030?
The interventions under investigation include: nusinersen (DRUG).
Who is sponsoring clinical trial NCT03878030?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03878030 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI